{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:56:42Z","timestamp":1784077002975,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtha.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:26:24Z","timestamp":1734092784000},"page":"989-996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the MRX PT DOAC assay for detection of clinically relevant factor Xa inhibitor drug levels"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-2924","authenticated-orcid":false,"given":"Brittany","family":"Salter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Moffat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Dobson-Storr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Broomhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"Onel\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Atalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Melika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj","family":"Mithoowani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.12.005_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for us medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/heartjnl-2022-321377","article-title":"Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019)","volume":"109","author":"Joy","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jtha.2024.12.005_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.12.005_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1055\/s-0042-1753485","article-title":"A\u00a0historical perspective on the reversal of anticoagulants","volume":"48","author":"Salter","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet\u00a0alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1060028015578451","article-title":"Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?","volume":"49","author":"Gosselin","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International\u00a0Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/03009734.2017.1370040","article-title":"A\u00a0novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)","volume":"122","author":"Lindahl","year":"2017","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jtha.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/bloodadvances.2020002335","article-title":"Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure","volume":"4","author":"Shaw","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.12.005_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet\u00a0alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/jnnp-2020-325456","article-title":"Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants","volume":"92","author":"Seiffge","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtha.2024.12.005_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12528","article-title":"Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: an observational study","volume":"5","author":"Sukumar","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-2261-1811","article-title":"Algorithm for rapid exclusion of clinically relevant plasma levels of direct oral anticoagulants in patients using the DOAC dipstick: an expert consensus paper","volume":"124","author":"Harenberg","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/jth.15884","article-title":"The myths behind DOAC measurement: analyses of prescribing information from different regulatory bodies and a call for harmonization","volume":"20","author":"Gosselin","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12959-024-00591-x","article-title":"Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban","volume":"22","author":"Onel\u00f6v","year":"2024","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2024.12.005_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2017.06.034","article-title":"An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants","volume":"157","author":"Sennesael","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijlh.12528","article-title":"Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays","volume":"38","author":"Gosselin","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-9560-12-7","article-title":"Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs","volume":"12","author":"Altman","year":"2014","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2024.12.005_bib23","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.5858\/arpa.2013-0750-OA","article-title":"Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban","volume":"138","author":"Gosselin","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtha.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1055\/s-0041-1732437","article-title":"Detection of direct oral anticoagulants in patient urine samples by prototype and commercial test strips for DOACs \u2013 a systematic review and meta-analysis","volume":"5","author":"Martini","year":"2021","journal-title":"TH Open"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:09:20Z","timestamp":1772327360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624007256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1538783624007256"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the MRX PT DOAC assay for detection of clinically relevant factor Xa inhibitor drug levels","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}